TENEX Drug Patent Profile

Which patents cover Tenex, and when can generic versions of Tenex launch?

Tenex is a drug marketed by Promius Pharma and is included in one NDA.

The generic ingredient in TENEX is guanfacine hydrochloride. There are seven drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the guanfacine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tenex

A generic version of TENEX was approved as guanfacine hydrochloride by WATSON LABS on October 17^th, 1995.

Summary for TENEX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	110
Patent Applications:	823
What excipients (inactive ingredients) are in TENEX?	TENEX excipients list
DailyMed Link:	TENEX at DailyMed

US Patents and Regulatory Information for TENEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-001	Oct 27, 1986		DISCN	Yes	No
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-002	Nov 7, 1988		DISCN	Yes	No
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-003	Nov 7, 1988		DISCN	No	No

Expired US Patents for TENEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-001	Oct 27, 1986
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-003	Nov 7, 1988
Promius Pharma	TENEX	guanfacine hydrochloride	TABLET;ORAL	019032-002	Nov 7, 1988

International Patents for TENEX

See the table below for patents covering TENEX around the world.

Country	Patent Number	Title	Estimated Expiration
France	1584670
Canada	959860	ACETYL-GUANIDINE DERIVATIVES ACETYL-GUANIDINE DERIVATIVES
Netherlands	6812271
Finland	48727

TENEX Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Tenex (Guanfacine Hydrochloride)

Introduction

Tenex, known generically as guanfacine hydrochloride, is a centrally acting antihypertensive agent with α2-adrenoceptor agonist properties. It is used primarily to treat high blood pressure and, in some cases, attention deficit hyperactivity disorder (ADHD). Here, we will delve into the market dynamics and financial trajectory of Tenex.

Market Overview

Usage and Indications

Tenex is prescribed for its antihypertensive properties, acting by stimulating central α2-adrenergic receptors to reduce sympathetic nerve impulses, thereby decreasing peripheral vascular resistance and heart rate[5].

Patient Demographics

While the primary use of Tenex is for hypertension, its application in ADHD treatment is also notable. However, the market trends for stimulants and non-stimulants in ADHD treatment show that non-stimulant medications like guanfacine have a specific niche. For instance, from 2012 to 2022, the use of non-controlled substances like guanfacine for ADHD saw a steady presence, with about 90% being existing prescriptions and around 5% being new therapy starts[1].

Market Trends

Prescription Patterns

The prescription patterns for Tenex and similar medications have shown significant changes over the years. From 2012 to 2022, there was a notable increase in the number of stimulant prescriptions, but the trend for non-stimulant ADHD medications like Tenex remained relatively stable. The average daily dose of stimulant medications, including those that might be used in conjunction with Tenex, showed a modest decline over time[1].

Impact of COVID-19

The COVID-19 pandemic had a significant impact on prescription patterns. There was a steep decline in stimulant prescriptions immediately after the pandemic restrictions were implemented, but by October 2020, these prescriptions rebounded to pre-pandemic levels. The use of telemedicine for new therapy starts (NTS) of stimulants, including potentially those involving Tenex, increased during this period but later decreased, though remaining above pre-pandemic levels[1].

Financial Aspects

Pricing and Affordability

The cost of Tenex can be substantial, with a supply of 100 tablets of the 1 mg oral tablet costing around $261 for cash-paying customers. However, generic versions of guanfacine are available at significantly lower prices, starting from around $19.25 for 30 tablets[2].

Revenue and Market Size

While specific revenue figures for Tenex are not readily available, the overall market for hypertension and ADHD treatments is substantial. The chronic pain market, which can sometimes overlap with hypertension and ADHD in terms of treatment options, is expected to grow significantly by 2032, driven by increasing prevalence of related conditions and new therapeutic options[4].

Competitive Landscape

Key Players

The market for antihypertensive and ADHD medications is competitive, with several key players. For hypertension, companies like Pfizer and Bayer are prominent. In the ADHD space, medications like Tenex compete with other non-stimulant options such as clonidine and newer therapeutic agents[4].

Generic Competition

The availability of generic guanfacine significantly impacts the pricing and market dynamics of Tenex. Generic versions are often preferred due to their lower cost, which can affect the sales and revenue of the branded product[2].

Financial Trajectory of Similar Companies

Tenax Therapeutics

Although Tenax Therapeutics is a different company focused on cardiovascular and pulmonary diseases, its financial trajectory can provide insights into the broader pharmaceutical market. Tenax Therapeutics reported a net loss of approximately $4.0 million in the third quarter of 2024 but raised significant funds through a private placement, indicating strong investor confidence in pharmaceutical research and development. This company's financial activities, such as raising $100 million and expanding clinical trials, highlight the ongoing investment in pharmaceutical research[3].

Key Takeaways

• Market Stability: Despite fluctuations due to the COVID-19 pandemic, the market for antihypertensive and ADHD medications, including Tenex, has shown resilience.
• Generic Competition: The availability of generic guanfacine significantly impacts the pricing and market dynamics of Tenex.
• Financial Investments: The pharmaceutical industry continues to attract significant investments, indicating a strong financial trajectory for companies involved in drug development and commercialization.
• Patient Demographics: The use of Tenex is influenced by patient demographics, with different age groups and genders showing varying prescription patterns.

FAQs

What is Tenex used for?

Tenex (guanfacine hydrochloride) is primarily used to treat high blood pressure and, in some cases, attention deficit hyperactivity disorder (ADHD).

How does Tenex work?

Tenex works by stimulating central α2-adrenergic receptors, which reduces sympathetic nerve impulses to the heart and blood vessels, thereby decreasing peripheral vascular resistance and heart rate[5].

What is the cost of Tenex?

The cost of Tenex can range from around $261 for a supply of 100 tablets of the 1 mg oral tablet for cash-paying customers. Generic versions are available at lower prices, starting from around $19.25 for 30 tablets[2].

How has the COVID-19 pandemic affected Tenex prescriptions?

The COVID-19 pandemic led to a temporary decline in stimulant prescriptions, including those that might involve Tenex, but these rebounded to pre-pandemic levels by October 2020. Telemedicine use for new therapy starts increased during this period[1].

What are the common side effects of Tenex?

Common side effects of Tenex include dry mouth, somnolence, asthenia, dizziness, and headache. Most of these reactions are mild and tend to disappear with continued dosing[5].

Is Tenex available in generic form?

Yes, a generic version of guanfacine is available, which is significantly cheaper than the branded product[2].